Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · IEX Real-Time Price · USD
4.360
-0.150 (-3.33%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Zevra Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Zevra Therapeutics stock have an average target of 20, with a low estimate of 15 and a high estimate of 25. The average target predicts an increase of 358.72% from the current stock price of 4.36.
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 3, 2024.
Analyst Ratings
The average analyst rating for ZVRA stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 3 | 3 | 3 |
| Buy | 0 | 0 | 1 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +244.04% | Apr 3, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 1, 2024 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Mar 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +244.04% | Mar 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $15 | Strong Buy | Maintains | $10 → $15 | +244.04% | Dec 28, 2023 |
Financial Forecast
Revenue This Year
29.45M
from 27.46M
Increased by 7.22%
Revenue Next Year
85.03M
from 29.45M
Increased by 188.76%
EPS This Year
-1.64
from -1.30
EPS Next Year
-0.60
from -1.64
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 39.8M | 103.9M | 179.6M | 283.1M | 328.2M |
| Avg | 29.4M | 85.0M | 148.7M | 234.9M | 292.9M |
| Low | 22.7M | 66.5M | 110.4M | 192.1M | 232.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 44.9% | 252.7% | 111.2% | 90.4% | 39.7% |
| Avg | 7.2% | 188.8% | 74.9% | 58.0% | 24.6% |
| Low | -17.5% | 125.8% | 29.8% | 29.2% | -0.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.40 | -0.26 | 0.98 | 2.77 | 3.16 |
| Avg | -1.64 | -0.60 | 0.34 | 1.86 | 2.60 |
| Low | -1.76 | -1.10 | -0.52 | 1.16 | 2.04 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 718.6% | 70.0% |
| Avg | - | - | - | 448.9% | 39.8% |
| Low | - | - | - | 241.5% | 9.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.